Clinical Trials Update: Sept. 29, 2006
Bladder Disorders Metastatic Cancer or Colorectal Cancer Bipolar Disorders
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
More than 33 million people in the U.S. have overactive bladder (OAB), with symptoms such as frequent urination, urgency, waking up at night to urinate, and wetting accidents. This is a research study of an FDA-approved medication to treat OAB. All participants will be given the active study medication and study-related care at no cost.
The research site is in Lawrenceville, NJ.
Metastatic Cancer or Colorectal Cancer
This trial will evaluate use of cetuximab, bevacizumab and biweekly infusional 5-FU/leucovorin (FOLF-CB) versus oxaliplatin, bevacizumab, and biweekly infusional 5-FU/leucovorin (Bev-FOLFOX) for first-line treatment of metastatic colorectal cancer. Volunteers with colorectal cancer that has spread to other parts of the body who have not had previous treatment for this cancer may be included.
The research site is in Gainesville, Fla.
This study will compare use of olanzapine versus divalproex to treat mild-to-moderate mania associated with bipolar disorder. Candidates 18-65 with a diagnosis of bipolar 1 disorder who are not rapid cycling may be eligible. Participants cannot have psychotic episodes or a current diagnosis of schizophrenia disorder, delirium disorder, a history of seizures, Parkinson's disease, HIV/AIDS, or hepatitis B or C.
The research site is in Daytona Beach, Fla.
Copyright 2006 Thomson CenterWatch. All rights reserved.